

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTIONS PASSED AT THE 5TH BOARD MEETING FOR FY2022

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Company had on 12 August 2022 issued a notice of board meeting to its directors in respect of the 5th board meeting for the financial year ending 31 December 2022 (“FY2022”), and the board meeting was duly convened by means of telephone conference on 22 August 2022. The said meeting was convened in compliance with the applicable Companies Law, Securities Law and the Articles of Association of the Company, and the following resolutions were discussed and passed by the 9 directors out of the full board of 9 directors:

1. That, upon nomination and deliberation at a meeting of the Office of General Manager of the Company and review by the Nomination Committee of the Company, the proposed appointment of Ms. Wang Lei (王磊) as General Manager of the Company, be approved.

Ms. Wang Lei, born in August 1971, is a senior engineer (senior title) with a postgraduate degree in applied chemistry and a Ph.D. degree in engineering. Ms. Wang joined the Company in July 1993, and successively worked in Da Ren Tang Pharmaceutical Factory, the Planning Office of Chinese Patent Medicine Department of the Company, the Industry Department of the Company, and Le Ren Tang Pharmaceutical Factory. From May 2013 to June 2013, Ms. Wang was a member of the Supervisory Committee of the Company, and from June 2014 to March 2018, she successively served as Deputy General Manager and General Manager of the Company. Ms. Wang was also a Director of the Company from May 2015 to May 2018. Since March 2018, she has successively served as Executive Deputy General Manager, General Manager and Vice Chairman of Tianjin Da Ren Tang Jingwanhong Pharmaceutical Co., Ltd. (天津达仁堂京万红药业有限公司). Since January 2022 to present, Ms. Wang served as the Deputy General Manager of the Marketing Management Centre of Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司).

2. That, the Company's proposed acquisition of part of the shareholding of NewScen Coast Bio-Pharmaceutical Co., Ltd. (天津中新科炬生物制药股份有限公司) (“**NewScen Coast**”) (the “**Proposed Acquisition**”) be approved.

As at the date of this announcement, NewScen Coast is an associate of the Company in which the Company holds approximately 26.29% shareholding and is the largest shareholder, and the Company's controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) (“**TPH**”) holds approximately 2.82% shareholding.

The Board approved that the Company shall, in phases, acquire up to 11,968,599 shares from the existing shareholders (excluding TPH) of NewScen Coast through transfer by agreement at a price

not exceeding RMB9.00 per share of NewScen Coast, with a total investment not exceeding RMB107,717,400, representing 1.69% of the latest audited net assets of the Company attributable to its parent company.

The Company will, on 22 August 2022, enter into a share transfer agreement with the two existing shareholders of NewScen Coast (being Wang Liangming (汪良明) (“**Mr. Wang**”) and Chen Zhe (陈喆) (“**Mr. Chen**”)), pursuant to which the Company shall purchase 3,075,000 shares in NewScen Coast held by Mr. Wang and 2,660,899 shares in NewScen Coast held by Mr. Chen, respectively, at the price of RMB9.00 per share. The Proposed Acquisition does not constitute an interested person transaction or a disclosable transaction for the purposes of Chapters 9 and 10 of the Listing Rules of SGX-ST.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
22 August 2022